NCT06945120 ACT Lung Health Intervention: Phase Two
| NCT ID | NCT06945120 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Dana-Farber Cancer Institute |
| Condition | Smoking Cessation |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2025-11-04 |
| Primary Completion | 2026-11-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 50 participants in total. It began in 2025-11-04 with a primary completion date of 2026-11-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to test a counseling and educational program designed to improve lung health through smoking cessation for Chinese and Korean American smokers at high risk for lung cancer.
Eligibility Criteria
Inclusion Criteria: * Self-identify as either Chinese or Korean * Speak either Korean, Mandarin, or English * Are 18 years of age or older * Are current smokers (i.e., have smoked at least 100 traditional cigarettes ever and have smoked at least one traditional cigarette within the prior 30 days) * Will live in the United States for the next 12 months Exclusion Criteria: * Hospitalization due to a serious mental illness (e.g., psychotic disorders) during the prior 6 months. * We will not include any of the following special populations: * Adults unable to consent. * Adults younger than 50 or older than 80 years * Individuals who are not yet adults (infants, children, teenagers) * Pregnant women * Prisoners
Contact & Investigator
Mary Cooley, PhD
PRINCIPAL INVESTIGATOR
Dana-Farber Cancer Institute
Frequently Asked Questions
Who can join the NCT06945120 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 100 Years, studying Smoking Cessation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06945120 currently recruiting?
Yes, NCT06945120 is actively recruiting participants. Contact the research team at mary_cooley@dfci.harvard.edu for enrollment information.
Where is the NCT06945120 trial being conducted?
This trial is being conducted at Boston, United States, Boston, United States.
Who is sponsoring the NCT06945120 clinical trial?
NCT06945120 is sponsored by Dana-Farber Cancer Institute. The principal investigator is Mary Cooley, PhD at Dana-Farber Cancer Institute. The trial plans to enroll 50 participants.